Celldex Therapeutics, Inc. — Director's Dealing 2020

Dec 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2020-12-14

Reporting Person: Wright Richard M. (Sr. VP & CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Common Stock	M	11457	$9.0165	Acquired	11665	Direct
2020-12-14	Common Stock	S	11457	$18.6065	Disposed	208	Direct
2020-12-14	Common Stock	M	9375	$2.78	Acquired	9583	Direct
2020-12-14	Common Stock	S	9375	$18.6065	Disposed	208	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-14	Incentive Stock Option	$9.0165	M	11457	Disposed	2028-06-13	Common Stock (11457)	Direct
2020-12-14	Incentive Stock Option	$2.78	M	9375	Disposed	2029-06-19	Common Stock (9375)	Direct

Footnotes

F1: On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.

F2: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019.

F3: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F4: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.